As amorphous materials become more mature and widely accepted by the industry, spray dryers are likely to continue to develop as a beneficial technology for poorly soluble oral drugs. However, its application in biopharmaceuticals, such as the isolation and preparation of peptides, proteins and monoclonal antibodies, may bring huge growth in the future.
Its cost and throughput advantages over traditional lyophilization, as well as its ability to handle more complex formulations and solvent systems, may drive its gradual introduction into these areas. Aseptic spray dryers are still in the early stages of implementation, but strong steps have been taken recently in the design of these units and the filling of aseptic powders (operating as complementary units). Another area of potential growth is the use of spray drying to produce inhalable medicines. A major disadvantage of traditional lactose blends is the need to balance the adhesion between the drug and the carrier, since a large amount of the drug cannot be separated from the lactose and inevitably deposits in the mouth/throat; spray drying can be achieved by preparing composite granules. Overcoming this challenge, where very high and reproducible breath ratios can be achieved by accurately fine-tuning the particle size distribution during development (as well as tight control during manufacturing).
https://www.stardrying.com/
